Vivos Inc. (OTCMKTS:RDGL - Get Free Report) was the recipient of a significant decrease in short interest in January. As of January 15th, there was short interest totalling 25,300 shares, a decrease of 61.0% from the December 31st total of 64,900 shares. Based on an average daily trading volume, of 3,461,200 shares, the days-to-cover ratio is currently 0.0 days.
Vivos Trading Down 2.3 %
Shares of Vivos stock traded down $0.00 on Tuesday, reaching $0.12. The stock had a trading volume of 450,769 shares, compared to its average volume of 1,424,192. The business's 50 day moving average is $0.11 and its two-hundred day moving average is $0.13. The company has a market cap of $54.90 million, a P/E ratio of -12.41 and a beta of 0.91. Vivos has a 1 year low of $0.05 and a 1 year high of $0.26.
Vivos Company Profile
(
Get Free Report)
Vivos Inc, a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals.
Featured Articles
Before you consider Vivos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivos wasn't on the list.
While Vivos currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.